Basic and clinical studies of biapenem (BIPM), a newly-developed carbapenem antibiotic for parenteral use, were carried out in surgical field, and the following results were obtained. 1) Antibacterial activity: MIC50/MIC90 (μg/ml) against Staphylococcus aureus, Esherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa isolated from surgical lesions were respectively measured to be 25/50, ≤0.20/≤0.20, ≤0.20/0.39, 0.39/0.78. 2) Penetration into bile: After 300mg of BIPM was administered to one of cholelithiasis after operation by intravenous drip infusion, bile and serum levels were measured. The maximum bile and serum levels were 1.4μg/ml and 20.7μg/ml. 3) Clinical results: BIPM was administered to 28 patients with surgical infection. Clinical response was excellent in 9, good in 17, fair in 1 and poor in 1, resulting in a 92.9% efficacy rate. The bacteriological efficacy was respectively evaluated to be eradicated in 19, replaced in 2, partially eradicated in 1, and persisted in 2 cases, showing a 87.5% eradication rate. No adverse reaction was noted. Abnormal laboratory findings were recognized in 6 cases.
|Number of pages||10|
|Publication status||Published - 01-01-1994|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases
- Drug Discovery